Gapping down
In reaction to earnings/guidance:
- JKS -10.9%, WDFC -7.3%, PSMT -3%, IMOS -0.6% (Q1 revs), TSM -0.5% (March Sales)
Other news:
- PRVB -37.9% (FDA identifies deficiencies in BLA application for teplizumab)
- ITRM -15.5% (discloses FDA notice that it needs more time to review materials that have been provided by the company)
- GSL -5.4% (stock offering)
- DLPN -4.7% (says some prior financials should no longer be relied upon due to accounting error)
- SNDX -4.6% (FDA grants Orphan Drug Designation to axatilimab)
- RMBL -4.4% (prices offering of 1,048,998 shares of its Class B Common Stock at $38.00 per share)
- KMPH -2.4% (amends licensing agreement with Gurnet Point Capital following FDA approval of AZSTARYS)
- UCTT -1.5% (prices offering of 3,181,818 shares of its common stock at $55.00 per share)
- ORTX -1% (ADS offering)
Analyst comments:
- CS -2.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- BTI -2.4% (downgraded to Neutral from Overweight at JP Morgan)
- ATUS -1.6% (downgraded to Neutral from Buy at Citigroup)
- BCC -1.2% (downgraded to Neutral from Buy at DA Davidson)
- CHUY -1.1% (downgraded to Hold from Buy at Stifel)
- GD -0.8% (downgraded to Underperform from Outperform at Wolfe Research)